VOR Company Profile and Key Details

VOR has shown weak momentum, losing -8.15% over the past week and -58.11% over the past quarter, though year-to-date performance is down -34.55%. Short-term trend indicators are bullishly aligned (SMA20 31.42%, SMA50 -8.65%, SMA200 -35.3%). The stock’s 14-day RSI is 55.8 (neutral), while the ATR of 1.79 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -77.92% below its high and over 454.16% above its low. Average 10-day trading volume of 1.82 million shares is slightly above the 3-month average of 1.57 million, indicating heightened recent market interest.

Vor Biopharma Inc. has 126.68 million shares outstanding. The public float is 52.66 million shares, elevated short interest at 41.28% of float. This equals 19.78 million shares. The short ratio is 4.26 days. Institutional investors hold 72.79% of the float. Insiders own 40.08%. 5AM Ventures VI, L.P. holds 1.77 million shares, PARMAR KUSH has 1.77 million shares and Reprogrammed Interchange LLC has 1.17 million shares. Over the past six months, insider transactions show net selling. They sold 6.94 million shares across 40 transactions.

Vor Biopharma Inc. (NASDAQ:VOR) closed at $14.53 USD, gaining $1.00 (7.39%) from the previous close of $13.53. The stock is currently mid-range between its 52-week high and low $2.62 and $65.80. With a market capitalization of about $99.59 million, Vor Biopharma Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.08). Key stats such as the average daily volume over the past year has been around 1.63 million shares, volume is running light vs its 52-week average. Headquartered in Cambridge, MA, Vor Biopharma Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jean-Paul Kress, the company employs approximately 159 people and listed since February 05, 2021. Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients.

Vor Biopharma Inc. generated EPS of -$386.85 over the past year. Five-year average earnings growth is -38.02%. Wall Street analysts project EPS growth of 45.54% annually over the next five years. The latest quarter delivered EPS of -$3.33. The next quarter is forecast at -$1.64. Next year's EPS is expected at $2.24. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 6 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $64.00 to $0.40. The high target offers 340.47% upside. The low target suggests -97.25% downside. The mean target is $21.26. This offers 46.32% upside. Vor Biopharma Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 13, 2025, missed forecasts by 8.82%. The prior quarter beat by 282.46%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in August 08, 2024.

Vor Biopharma Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $14.59. This means the shares are trading near this model’s fair value.

Vor Biopharma Inc. (NASDAQ:VOR) shares are down -34.55% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Vor Biopharma Inc. trading at a premium to the broader market with a P/E of -0.04. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $21.26, suggesting 46.32% upside. Our AI forecast model points to short-term weakness (-13.49% over two weeks), a medium-term fall (-73.98% over three months), and a longer-term gain (50.1% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Vor Biopharma Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -13.49%, with price expected at $12.57 by January 07, 2026, within a range of $7.78 to $17.17 3-Month Outlook: Projected fall of -73.98%, reaching $3.78 by March 23, 2026, with a range of $2.41 to $4.95. 1-Year Outlook: Projected gain of 50.1%, with price at $21.81 by December 24, 2026, within a range of $0.00 to $30.49.

Vor Biopharma Inc. trades at a P/E ratio of -0.04, slightly below the S&P 500 average, with a price-to-sales ratio of 27.02 and a price-to-book ratio of -0.04 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.69, also above market averages.